- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | CERO THERAPEUTICS HOLDINGS, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 14.04. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 14.04. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial | 155 | GlobeNewswire (Europe) | Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF) SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings... ► Artikel lesen | |
| 01.04. | CERO THERAPEUTICS HOLDINGS, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 30.03. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial | 191 | GlobeNewswire (Europe) | Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH SAN FRANCISCO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.... ► Artikel lesen | |
| 11.03. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Provides Shareholder Update | 212 | GlobeNewswire (Europe) | Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, strategic engagement, and continued support from lead... ► Artikel lesen | |
| 13.02. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.02. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient | 1 | GlobeNewswire (USA) | ||
| CERO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 03.02. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.01. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 07.01. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion-Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML | 153 | GlobeNewswire (Europe) | Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings... ► Artikel lesen | |
| 19.12.25 | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 17.12.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1) | 201 | GlobeNewswire (Europe) | Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1 SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| 05.12.25 | CERO THERAPEUTICS HOLDINGS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 02.12.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Trading on OTCQB Market | 204 | GlobeNewswire (Europe) | Company's Shares Will Continue to Trade Under Ticker CERO SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo" or the "Company"),... ► Artikel lesen | |
| 02.12.25 | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 19.11.25 | CERO THERAPEUTICS HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.11.25 | CERO THERAPEUTICS HOLDINGS, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 05.11.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing | 233 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new... ► Artikel lesen | |
| 30.10.25 | CERo Therapeutics denied Nasdaq listing, seeks OTC markets | 24 | Seeking Alpha |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,427 | -3,09 % | PacBio Stock Up on New FFPE Workflow Boosting Cancer Sequencing | ||
| CYTOMX THERAPEUTICS | 4,180 | +0,63 % | CytomX-Aktie: sharedealsPlus-Highflyer schießt auf +1.835% Kursgewinn | Die Aktie von CytomX Therapeutics gehört weiterhin zu den spektakulärsten Turnaround-Stories im Biotech-Sektor. Seit ihrem Vorjahrestief hat sich der Kurs des sharedealsPlus-Tipps inzwischen um rund... ► Artikel lesen | |
| CARISMA THERAPEUTICS INC | 0,127 | -100,00 % | CSE Bulletin: Name and Symbol Change - Carmanah Minerals Corp. (CARM) | Le 7 avril/April 2026
Carmanah Minerals Corp. (CARM) has announced a name and symbol change to Skull Ridge Gold Corp. (SKUL).
Shares will begin trading under the new name and symbol and with a... ► Artikel lesen | |
| CAPRICOR | 30,390 | +4,72 % | Top 10 Healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x | ||
| CORMEDIX | 6,144 | -4,66 % | CorMedix, Inc.: CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | - Q4 2025 Net Revenue of $128.6 million - Pro Forma Full Year 2025 Net Revenue of $401.3 million - Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million - Conference Call Scheduled... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 5,770 | -1,37 % | Citizens initiates Minerva Neurosciences stock at outperform, $14 target | ||
| REPLIMUNE | 1,794 | +2,90 % | Weekly Buzz: FDA Okays Travere Therapeutics, Royal Philips; Rejects Replimune; American Industrial Partners Snaps Up Avanos Medical; PDS Biotechnology, Hoth Therapeutics, Spyre Therapeutics, Paces Trials | INDIANAPOLIS (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., Taiwan, and Europe, alongside FDA rejections, collaborations, acquisitions, and positive... ► Artikel lesen | |
| VALERIO THERAPEUTICS | 0,137 | -3,52 % | Valerio Therapeutics Announces the Appointment of Professor Eric Vivier as Observer to Its Board of Directors | Regulatory News:
Valerio Therapeutics ("Valerio Therapeutics" or the "Company") (Euronext Growth Paris: ALVIO) announces the appointment of Professor Eric Vivier as an Observer to its Board of... ► Artikel lesen | |
| RANI THERAPEUTICS | 0,971 | 0,00 % | Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy | SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery... ► Artikel lesen | |
| IO BIOTECH | 0,048 | 0,00 % | IO Biotech Provides Corporate Update | Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| ALTO NEUROSCIENCE | 27,240 | -1,70 % | Alto Neuroscience, Inc.: Alto Neuroscience to Participate in Upcoming Investor Conferences | Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that... ► Artikel lesen | |
| OSR HOLDINGS | 0,597 | +4,75 % | OSR Holdings, Inc.: OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note | BELLEVUE, WA / ACCESS Newswire / April 9, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) ("OSR Holdings" or the "Company") today announced a strategic transaction for capital structure optimization with White... ► Artikel lesen | |
| CG ONCOLOGY | 70,40 | -4,14 % | CG Oncology-Aktie erreicht Rekordhoch von 72,29 US-Dollar | ||
| KYMERA THERAPEUTICS | 86,93 | -0,82 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma | KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track... ► Artikel lesen | |
| QIAGEN | 34,950 | 0,00 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen |
Das Unternehmen CERO THERAPEUTICS HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,000 (+0,11 %) liegt der Kurs bei 0,095 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERO THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.